Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Higgins

Showing results (781-790 of 837) with videos related to

Pageof 84
Sort By:
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 12, 2020
Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan MedicineKayte Spector-Bagdady, Peter D R Higgins, Keith D Aaronson, et al.
American Journal of Obstetrics & Gynecology MFM|December 21, 2020
Defining the upper limit of the second stage of labor in nulliparous patientsCatherine L Finnegan, Naomi Burke, Fionnuala Breathnach, et al.
American Journal of Obstetrics and Gynecology|July 28, 2012
Placental pathology, birthweight discordance, and growth restriction in twin pregnancy: results of the ESPRiT StudyEtaoin M Kent, Fionnuala M Breathnach, John E Gillan, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2023
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance studySéverine Vermeire, Silvio Danese, Wen Zhou, et al.
Journal of Crohn'S & Colitis|February 5, 2019
CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's DiseaseShrinivas Bishu, Mohammed El Zaatari, Atsushi Hayashi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 16, 2025
Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing ColectomyCharlotte Larson, Jeffrey A Berinstein, Nicholas Tedesco, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic ReviewCalen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, et al.
Gastroenterology|November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
Pageof 84

Showing results (781-790 of 837) with videos related to

Sort By:
Pageof 84
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 12, 2020
Coronavirus Disease 2019 (COVID-19) Clinical Trial Oversight at a Major Academic Medical Center: Approach of Michigan MedicineKayte Spector-Bagdady, Peter D R Higgins, Keith D Aaronson, et al.
American Journal of Obstetrics & Gynecology MFM|December 21, 2020
Defining the upper limit of the second stage of labor in nulliparous patientsCatherine L Finnegan, Naomi Burke, Fionnuala Breathnach, et al.
American Journal of Obstetrics and Gynecology|July 28, 2012
Placental pathology, birthweight discordance, and growth restriction in twin pregnancy: results of the ESPRiT StudyEtaoin M Kent, Fionnuala M Breathnach, John E Gillan, et al.
The Lancet. Gastroenterology & Hepatology|September 8, 2023
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance studySéverine Vermeire, Silvio Danese, Wen Zhou, et al.
Journal of Crohn'S & Colitis|February 5, 2019
CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's DiseaseShrinivas Bishu, Mohammed El Zaatari, Atsushi Hayashi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 16, 2025
Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing ColectomyCharlotte Larson, Jeffrey A Berinstein, Nicholas Tedesco, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic ReviewCalen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, et al.
Gastroenterology|November 8, 2021
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.
Pageof 84